LifeArc and PharmEnable team up to discover novel oral antiviral drugs to treat coronaviruses
Aiming to produce an oral therapeutic with broad applicability across coronaviruses.
LifeArc’s Opportunity Assessment Group (OAG) team played a vital role in supporting the UK’s #COVID19 #Theraputics… https://t.co/qkgycA5TOe
Novartis BIOME UK announces selection for the HealthHub 21 Challenge, in collaboration with KQ Labs and LifeArc
Novartis UK announces companies selected for the Novartis BIOME UK HealthHub 21 Challenge
LifeArc publishes expert advice to support work around repurposing medicines
Guide will support researchers and charities who focus on diseases which have few effective therapies
PostEra and LifeArc collaborate on novel open science initiative to develop new antiviral for COVID-19
£100,000 grant to develop a globally-accessible, oral antiviral as part of the COVID Moonshot initiative
KQ Labs opens applications for health start-ups for its annual accelerator programme
This year's programme delivered by the Francis Crick Institute and funded by LifeArc
Advise & Connect: LifeArc offers expertise and funding to help tackle COVID-19
Access our advice, network and potentially more
LifeArc and the MND Association commit £1m to boost search for new treatments
Bolstered by the fundraising efforts of Leeds Rhinos’ coach, Kevin Sinfield
Action Medical Research and LifeArc announce joint funding awards for translational research into children’s rare diseases
Third joint funding round of up to £1 million
LifeArc invests in Cumulus Neuroscience
Investment part of £6 million funding round led by Dementia Discovery Fund, supported by UK Future Fund